CLAIMS

1. Use of a composition comprising a highly immunogenic antigen, a molecule that binds surface CD40 receptors to deliver cellular activation signals and an inflammatory type 1 cytokine or chemokine ("aTh1 composition") in the preparation of a medicament for the treatment or prevention of HIV in a patient.

2. Use according to Claim 1, in which the medicament comprises an intradermal dose of the aTh1 composition and an intravenous dose of the aTh1 composition.

3. Use according to Claim 1 or 2, in which the intradermal dose of the aTh1 composition when administered to the patient increases the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection.

4. Use according to Claim 1, 2 or 3, in which the intravenous dose of the aTh1 composition when administered to the patient expands and activates the CD4+ Th1 memory cells in the patient.

5. Use according to any preceding claim, in which the titer is increased by administering at least two intradermal doses of aTh1 composition, in which both of the doses are at the same location.

6. Use according to Claim 5, in which the interval between the intradermal doses is between about 3 days and about a week.

7. Use according to Claim 5, further comprising an additional two intradermal doses of the aTh1 composition at a location different than the location of the first two intradermal doses.

8. Use according to Claim 7, in which the at least one intravenous dose is administered within about 3 days of the last intradermal dose.

9. Use according to Claim 7, in which the intravenous dose is administered at about the same time as the last intradermal dose.

10. Use according to any preceding claim, in which the patient is concurrently treated with highly active antiretroviral therapy (HAART).

11. Use according to any preceding claim, in which the aTh1 composition comprises allogeneic activated CD4+ T-cells.

12. Use according to any preceding claim, in which the latent viral load is reduced or eliminated in the patient.